Anna Brouwer

2 39 Prolonged cone b-wave is associated with severity of inflammation procedures were used and were supervised by the same physicist, to ensure that the reference data were representative. An ERG response was considered as abnormal if amplitudes were below the 5 th percentile, or implicit times were above the 95 th percentile, or both (see Supplemental table 6 for cut off values). ERG response abnormalities were then categorized based on the measuring conditions (LA 0.3-10.0 cds/m 2 (single flash cone response), LA 3.0 cds/m 2 30 Hz flicker response (cone response), DA 0.01 cds/m 2 (single flash rod response), or DA 3.0-30.0 cds/m 2 (single flash combined rod/ cone response)) and which part of the response was abnormal (a-wave, b-wave, amplitudes and/or implicit times). In order for 1 of these categories to be defined as abnormal, the same type of ERG abnormality needed to be present in at least two consecutive flash strengths, except for the rod ERG, were the DA 0.01 cds/m 2 needed to be abnormal. So, if 2 ERG responses of consecutive flash strengths of the LA ERG showed a prolonged implicit time of the b-wave, the implicit time of the cone b-wave was defined as abnormal. B/a wave ratios were also evaluated. Clinical parameters Medical records were reviewed for age, sex, medical history, uveitis diagnosis, and anatomical localization of uveitis. The patient’s age at diagnosis was recorded. Uveitis activity was graded according to the Standardization of Uveitis Nomenclature criteria: cell grade in the anterior chamber, cell grade in the vitreous, flare, and vitreous haze. 11 The presence of posterior synechiae, corneal clarity, lens clarity, macular lesions, snowballs, snow banking, vasculitis, glaucoma, and the appearance of the optic disc (hyperemia, edematous, pale) were also noted. Additional information included whether patients were currently being treated with systemic steroids, disease-modifying antirheumatic drugs (DMARDS) (i.e. methotrexate (MTX), azathioprine, mycophenolate mofetil, mycophenolate sodium, cyclosporine, or cyclophosphamide), or biologicals (adalimumabor infliximab). Patients were also asked if they had been treated with a periocular/intraocular corticosteroid injection (betamethasone acetate 2.7 mg/bethamethasone, or sodium phosphate 3 mg periocular, up to 1 month prior to ERG. Triamcinolone 40 mg periocular, up to 3 months prior to ERG. Intravitreal dexamethasone 0.7 mg implant, up to 3 months prior to ERG). All patients except 2 had undergone optical coherence tomography (OCT) (Cirrus HD OCT 5000, Zeiss Meditec, Dublin, California) examination on the same day as the ERG measurement, from which the presence of cysts (cystoid macular edema (CME), sub-retinal fluid, epiretinal membranes and central retinal thickness (CRT) were noted per eye.